Skip to content

Advertisement

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Clinical relevance of molecular identification of microorganisms and detection of antimicrobial resistance genes in bloodstream infections of paediatric cancer patients

BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:462

https://doi.org/10.1186/s12879-016-1792-8

  • Received: 24 February 2016
  • Accepted: 21 August 2016
  • Published:
Open Peer Review reports

Abstract

Background

Bloodstream infections (BSIs) are the major cause of mortality in cancer patients. Molecular techniques are used for rapid diagnosis of BSI, allowing early therapy and improving survival. We aimed to establish whether real-time quantitative polymerase chain reaction (qPCR) could improve early diagnosis and therapy in paediatric cancer patients, and describe the predominant pathogens of BSI and their antimicrobial susceptibility.

Methods

Blood samples were processed by the BACTEC system and microbial identification and susceptibility tests were performed by the Phoenix system. All samples were screened by multiplex 16 s rDNA qPCR. Seventeen species were evaluated using sex-specific TaqMan probes and resistance genes blaSHV, blaTEM, blaCTX, blaKPC, blaIMP, blaSPM, blaVIM, vanA, vanB and mecA were screened by SYBR Green reactions. Therapeutic efficacy was evaluated at the time of positive blood culture and at final phenotypic identification and antimicrobial susceptibility results.

Results

We analyzed 69 episodes of BSI from 64 patients. Gram-positive bacteria were identified in 61 % of the samples, Gram-negative bacteria in 32 % and fungi in 7 %. There was 78.2 % of agreement between the phenotypic and molecular methods in final species identification. The mecA gene was detected in 81.4 % of Staphylococcus spp., and 91.6 % were concordant with the phenotypic method. Detection of vanA gene was 100 % concordant. The concordance for Gram-negative susceptibilities was 71.4 % for Enterobacteriaceae and 50 % for Pseudomonas aeruginosa. Therapy was more frequently inadequate in patients who died, and the molecular test was concordant with the phenotypic susceptibility test in 50 %.

Conclusions

qPCR has potential indication for early identification of pathogens and antimicrobial resistance genes from BSI in paediatric cancer patients and may improve antimicrobial therapy.

Keywords

  • Febrile Neutropenia
  • mecA Gene
  • Blood Culture Bottle
  • Phenotypic Method
  • Paediatric Cancer Patient

Background

Chemotherapy for childhood cancer is one of the greatest successes of modern medicine and the overall survival is now over 70 %. However myelossupression is a consequence of virtually all chemotherapy regimens and profound neutropenia (<0,5 × 109) is a major risk factor for overwhelming infections [1].

The relative frequency of different organisms causing bacterial infection may vary with time period and geographical location. Regardless of these variations in causative organism, and the widespread use and availability of powerful antibiotics, bacteremia/sepsis remains the most important independent prognostic marker for mortality in children with cancer who have febrile neutropenia. A diagnosis of sepsis or bacteremia increased in 10-fold increase risk of death [2].

In 40 % of children that have clinical diagnosis of sepsis and 75 % of those with high-risk FN, the microorganisms cannot be detected by currently available conventional microbiological techniques [3]. Early empirical treatment of fever in cancer patients remains the standard of care for the management of febrile neutropenia (FN).

In this context, our group developed an in-house, real-time, quantitative polymerase chain reaction (qPCR) directly from BACTEC blood culture (BC) bottles to identify the main pathogens and important resistance genes causing bloodstream infection (BSI) [4]. The aim of this study was to evaluate if this technique could anticipate and improve the diagnosis and therapy in paediatric cancer patients. The secondary objective was to describe the main pathogens of BSI and their antimicrobial susceptibilities.

Methods

Study design

Prospective study between March 2011 and March 2012 at the Institute of Paediatric Oncology, São Paulo, Brazil. Informed consent was obtained from all patients and the study was approved by the Clinical Research Ethics Committee of the Federal University of São Paulo. The samples were collected as part of standard care from patients suspected of BSI in the hospital. BSI was defined as the isolation of a bacterial or fungal pathogen from at least one BC.

All episodes of BSI were sub-classified as single agent (Gram-positive bacteria, Gram-negative bacteria, or fungi) or polymicrobial if two or more pathogens were isolated from a single BC.

We included only the BSI episodes for which BACTEC bottles were available for molecular tests without selection. We excluded polymicrobial episodes because it is not feasible to compare the conventional method with the molecular method if more than one agent grows in the same BC.

Data collection

Clinical data and bloodstream isolates were prospectively collected by local infection control practitioners.

Definitions

Neutropenia was defined as an absolute neutrophil count of <500 cells/mm3 within 48 h after onset of bacteraemia [5]. Sepsis was defined as systemic inflammatory response syndrome in the presence of suspected or proven infection and organ dysfunction, according to international consensus guidelines. Septic shock was defined as sepsis with systolic blood pressure <90 mmHg that did not respond to adequate fluid resuscitation, and necessitated the use of a vasopressor. Severe sepsis was defined as inflammatory response syndrome triggered by a microorganism, identified or not, plus one of the following: cardiovascular organ dysfunction or acute respiratory distress syndrome; or dysfunction of two or more other organs: neurological, renal or hepatic [6].

Patients without any identifiable source of infection were classified as primary bacteraemia. Secondary BSIs were regarded as those with a clear source of bacteraemia other than a central line. Sources of secondary BSI were identified by culture of samples obtained from distant sites that yielded the same pathogen with an identical resistance pattern. Distant sites were sites other than a central line where an infection was diagnosed (e.g. pneumonia, urinary tract infection or abdominal infection). Intensive care unit (ICU) stay was defined as current stay in the ICU at onset of bacteraemia, regardless of previous history of ICU admission.

Empirical antimicrobial therapy was instituted according to the standard protocol of the institution [7] at the time of fever and suspicion of BSI after collection of blood culture. Antimicrobial therapy was analysed in two periods: Period 1: antibiotics in use when the Gram stain test of a positive bloodstream culture was available to the physician; and Period 2: antibiotics in use when the final results of microbial identification and antimicrobial susceptibility test were reported to the physician. Antimicrobial therapy was considered adequate if the treatment regimen included one or more antibiotics active in vitro against the microorganism identified by phenotypic tests.

Mortality associated with infection was defined as death within 14 days of bacteraemia and there was no other explanation for that.

Microbiological features

BCs were performed using the BACTEC 9240 instrument (Becton & Dickinson, Microbiology Systems, Cockeysville, MD, USA). Identification at the species level and susceptibility testing were performed using the automated system Phoenix 100 (Becton & Dickinson Microbiology Systems). Minimum inhibitory concentration (MIC) determination was done by E test (AB Biodisk, Sweden) for oxacillin and carbapenems and by agar dilution for vancomycin, to confirm resistant phenotypes.

Molecular detection of microorganisms and resistance genes

Total DNA was extracted from 500 μL of positive or negative BC broth after incubation on BACTEC 9240, using the phenol–chloroform method (Brazol; LGC Biotechnologia, Cotia, Brazil) with 300-mg glass beads (0.3-mm diameter; Scientific Industries, Bohemia, NY, USA) and processed in a disruptor Genie (Scientific Industries) for 10 min to achieve cell lysis [4].

Real-time qPCR was performed as follows according to the protocols published by Menezes et al. in 2013 [4, 8]. Taqman-based multiplex detection of 16S rDNA gene with Gram-positive- and Gram-negative-specific probes; single SYBR green detection of each following resistance genes blaSHV, blaTEM, blaCTX-M, blaIMP, blaSPM, blaGIM, blaSIM blaVIM, blaKPC, vanA, vanB and mecA; and single Taqman-based detection of Enterococcus spp., coagulase-negative Staphylococcus (CoNS), Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Salmonella spp., Serratia marcescens, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Mycobacterium tuberculosis, Aspergillus spp., Candida spp. and Fusarium spp. were performed on an ABI 7500 real-time PCR System (Applied Biosystems, Foster City, CA, USA) instrument and quantified online and at the endpoint with sequence detection system software (version 2.0; Applied Biosystems) [4]. The primers were checked for specificity in a BLAST search available through the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi). A primer set for the haemochromatosis gene was designed as an internal control for DNA extraction.

Resistance gene amplification by SYBR Green monoplex real-time PCR was performed in a 25-μL reaction mixture containing 12.5 μL Platinum SYBR Green qPCR SuperMix (Invitrogen, Carlsbad, CA, USA), 0.5 μM each primer, and 5 μL purified DNA extracted from samples. The real-time PCR conditions were as follows: 50 °C for 2 min and 95 °C for 10 min; 40 cycles of 95 °C for 15 s and 60 °C for 60 s; and a melting curve step (from 68 to 95 °C in increments of 0.5 °C/s). The metallo-β-lactamase amplification was performed by SYBR-based multiplex real-time PCR.

The samples with discordant antimicrobial resistance results between molecular and phenotypic analyses were submitted to a qPCR assay directly from of the isolates strains. For methicillin-resistant Staphylococcus strains with discordant results, we determined the MIC for oxacillin with E test (fabricante) and the diameter zone for cefoxitin with the disc diffusion method following the Clinical and Laboratory Standards Institute recommendations.

Data collection was performed using SSPS version 17.0 software (SPSS Inc., Chicago, IL, USA) and Microsoft Office Excel 2010 (Microsoft, Redmond, WA, USA).

Results

Study population and patients characteristics

We identified 168 episodes of BSI, 81 episodes were included in the study with BACTEC BC bottles and were randomly available for molecular tests. Twelve episodes with polymicrobial culture results were excluded and our final data comprised 69 episodes of BSI from 64 patients.

Patients had a mean age of 7.8 years (range 0–22 years), and 57.8 % were male. The underlying diseases were: 20 % (13/64) acute lymphoid leukaemia; 19 % (12/64) central nervous system tumour; 14 % (9/64) acute myeloid leukaemia (AML); 9 % (6/64) non Hodgkin’s lymphoma; 8 % (5/64) neuroblastoma; 6 % (4/64) retinoblastoma; 5 % (3/64) osteosarcoma; 3 % (2/64) Ewing’s sarcoma; 2 % (1/64) Wilms’ tumour; and 20 % (13/64) others less common childhood tumours.

Among the potential factors predisposing to BSI, a central line catheter was present in 83 % (57/69), previous antimicrobial therapy was administered in 54 % (37/69), and neutropenia was present in 61 % (42/69). At onset of clinical evaluation, the use of antimicrobial therapy was observed in 85 % (59/69), sepsis was present in 68 % (47/69), septic shock occurred in 4 % (4/69), and severe sepsis in 3 % (2/69). Primary bacteraemia occurred in 91 % (63/69). Among secondary BSI caused by Gram-positive bacteria, the skin was the source in 60 %, followed by lungs and intestinal tract. In Gram-negative BSI, only one pulmonary secondary episode of BSI was identified.

Sixteen patients died during the study period, and six of these episodes occurred within 14 days and were related to BSI.

Phenotypic bacterial identification

Among 69 BSI episodes, 61 % (42/69) were caused by Gram-positive bacteria, 32 % (22/69) by Gram-negative bacteria, and 7 % (5/69) by fungi (Table 1). The three major pathogens of BSI were: CoNS in 26 % (18/69), followed by S. aureus in 13 % (9/69), and P. aeruginosa in 12 % (8/69). Five episodes were caused by fungi: Candida tropicalis, Candida parapsilosis, Candida guillermondi, Candida lusitaniae and Rhodotorula spp. (Table 1).
Table 1

Rank order of bloodstream pathogens isolated from BSI in paediatric cancer patients

Agents

69 (100 %)

 Gram positive

42 (61)

  CoNS

18 (26)

  Staphylococcus aureus

9 (13)

  Viridans group Streptococcus

6 (9)

  Streptococcus spp.

3 (4)

  Corynebacterium spp.

2 (3)

  Enterococcus spp.

2 (3)

  Other Gram positive

2 (3)

 Gram negative

22 (32)

  Pseudomonas. aeruginosa

8 (12)

  Escherichia coli

6 (9)

  Klebisiella pneumoniae

3 (4)

  Enterobacter cloacae

2 (3)

  Other Gram negative

3 (4)

 Fungi

5 (7)

  Candida tropicalis

1 (1)

  Candida parapsilosis

1 (1)

  Candida guillermondi

1 (1)

  Candida lusitaniae

1 (1)

  Rhodotorula spp.

1 (1)

CoNS Coagulase negative Staphylococci

Comparison of molecular with phenotypic identification methods

We performed phenotypic (automated) and molecular (qPCR) method for 69 positive samples taken directly from BC bottles and compared both methods. The overall concordance was 78.2 % for final species identification.

Among 42 samples positive for Gram-positive bacteria detected by BC processing, 36 were positive by Gram-postive 16 rDNA gene probe. Of these 36, 27 were identified at specie level by qPCR, 8 were identified by DNA sequencing and 7 were not identified. Three samples were discordant; in two of them the molecular method was not able to identify any microorganism, and one BC showed S. aureus and CoNS by qPCR. For 22 samples with Gram-negative isolates identified by BC processing, we observed a concordance of 81.8 % (18/22) with the molecular method. In two of these samples, qPCR was not able to identify the species, and in another two samples, the methods were discordant for species identification (Table 2).
Table 2

Discordant episodes between phenotypic and molecular tests of isolates from BSI in paediatric cancer patients

Episode

Phenotypic method

Molecular method

24

Staphylococcus warneri

Negative

29

Staphylococcus aureus

Negative

47

Staphylococcus aureus

CoNS

5

Escherichia coli

Negative

59

Pseudomonas aeruginosa

Negative

68

Burkholderia cepacia

CoNS/Ralstonia pickettii

CoNS Coagulase negative Staphylococci

Methicillin resistance was detected in 88 % (24/27) of the 27 Sthaphylococcus spp. samples identified by the phenotypic method. The mecA gene was detected in 22/24, corresponding to 91.6 % of concordance.

Two strains were identified as Enterococcus spp., and one of them was resistant to vancomycin by the phenotypic method. There was 100 % of concordance with detection of vanA by the molecular method.

The qPCR for extended spectrum β-lactamase (ESBL) coding genes was concordant with the phenotypic susceptibility profile test in 71.4 % (10/14) for Enterobacteriaceae.

Among four discordant samples, two were E. coli and had phenotypic detection of ESBL but no resistance gene was detected by the molecular method. One sample positive for E. coli with susceptibility to cephalosporins showed blaCTX, which was not detected directly from the isolated colony. The last discordant sample was positive for E. cloacae, with resistance to cephalosporins, but no resistance gene was detected. We did not detect any Enterobacteriaceae resistant to carbapenems by the phenotypic method and by the molecular method for blaKPC, blaIMP and blaVIM (Table 3).
Table 3

Resistance genes identified by molecular method and antimicrobial susceptibility for Gram-negative BSI

Episode

Phenotypic method

Resistance gene

Cefepime susceptibility

Meropenem susceptibility

1

Klebsiella pneumoniae

Negative

Susceptible

Susceptible

2

Acinetobacter baumannii

Negative

Susceptible

Susceptible

5

Escherichia coli

Negative

Resistant

Susceptible

6

Escherichia coli

Negative

Susceptible

Susceptible

8

Serratia marcescens

Negative

Susceptible

Susceptible

11

Enterobacter cloacae

Negative

Susceptible

Susceptible

16

K. pneumoniae

Negative

Susceptible

Susceptible

17

Klebsiella oxytoca

Negative

Susceptible

Susceptible

18

Achromobacter spp.

Negative

NT

NT

21

Escherichia coli

Negative

Susceptible

Susceptible

25

Enterobacter cloacae

Negative

Resistant

Susceptible

32

Pseudomonas putida

Negative

NT

NT

38

Pseudomonas aeruginosa

Negative

Resistant

Resistant

41

Klebsiella pneumoniae

bla TEM bla CTX

Resistant

Susceptible

43

Escherichia coli

bla CTX

Susceptible

Susceptible

46

Pseudomonas aeruginosa

bla SPM

Resistant

Resistant

49

Escherichia coli

Negative

Resistant

Susceptible

50

Pseudomonas aeruginosa

Negative

Resistant

Susceptible

54

Citrobacter freundii

bla CTX

Resistant

Susceptible

59

Pseudomonas aeruginosa

Negative

Resistant

Resistant

65

Escherichia coli

Negative

Susceptible

Susceptible

68

Burkholderia cepacia

Negative

NT

Resistant

NT not tested

Eight samples were positive for non-fermenting Gram-negative bacteria by the phenotypic method, and qPCR for resistance genes was performed in seven, we excluded the Achromobacter spp. sample.

Carbapenem resistance Pseudomonas aeruginosa was phenotypically detected in four samples while two samples were negative for blaSPM gene. There was 50 % concordance between both methods. One of these samples had the blaSPM resistance gene detected when testing the isolate strain (Table 3).

Five samples were positive for fungi, four Candida spp. and one Rhodotorula spp., and the molecular method was able to identify 80 % of the samples with Candida.

Antimicrobial therapy evaluation and death

Regarding antimicrobial therapy in Period 1, we observed inadequacy in 43 %. All except one episode were submitted to medical intervention at that time. In Period 2, the inadequacy remained in 12 % of episodes.

Death occurred in 16 % (11/69) of all the BSI episodes, and six of these episodes occurred within 14 days and were related to the BSI. The molecular method was concordant with phenotypic identification of the agent in 50 % of these episodes. Therapy in Period 1 was inadequate in patients whose death was related to BSI (5/6). In Period 2, three of them remained inadequate even after intervention. In these cases, we were able to identify blaSPM in P. aeruginosa and vanA in Enterococcus faecium by molecular test (Table 4).
Table 4

Phenotypic susceptibility, molecular tests and antimicrobial therapy of patients with death related to BSI

Episode

Underlying disease

Method

Phenotypic susceptibility

Resistance gene

Antimicrobial therapy

Phenotypic

Molecular

Cefepime

Meropenen

Vancomycin

Period 1

Period 2

5

AML

E. coli

Negative

Resistant

Susceptible

NA

Neg

Modified

Adequate

31

Other

C. tropicalis

Candida spp.

NA

NA

NA

NA

Adequate

Adequate

46

Wilms’ tumour

P. aeruginosa

P. aeruginosa

Resistant

Resistant

NA

bla SPM

Modified

Inadequate

56

ALL

C. lusitanae

Negative

NA

NA

NA

NA

Modified

Inadequate

58

ALL

P. aeruginosa

Negative

Resistant

Resistant

NA

Neg

Modified

Adequate

69

RMS

E. faecium

Enterococcus spp.

NA

NA

Resistant

vanA

Modified

Inadequate

ALL acute lymphoid leukaemia, RMS Rhabdomyosarcoma, Neg negative, NA not applicable

Discussion

The strategy of using empirical antibiotic therapy has greatly influenced the outcome of fever in paediatric cancer patients. Unfortunately, BC can identify pathogens in only 40 % of children with fever and can take >24 h to yield a report [3].

We evaluated 69 episodes of BSI from 64 patients. The predominant underlying disease was haematological malignancy, this group of patients constitute the group of major risk for development of invasive bacterial infections, due to aggressive chemotherapy that results in long periods of neutropenia [9].

In our study, more than half of our patients were neutropenic, which has been recognised as an important risk factor for life-threatening infection since the 1960s when Bodey et al. identified a strong inverse correlation between the degree of neutropenia and the probability of infection [1012].

We found a predominance of Gram-positive bacteria followed by Gram-negative bacteria, and fungi. Although we only studied a small sample, our results agree with our historic series and with the literature [7, 9, 13].

Among Gram-positive bacteria, CoNS was the main agent found, followed by Staphylococcus aureus which agrees with most epidemiological studies in this setting and is related with catheter implantation [14, 15].

Complications of S. aureus infection have been reported in paediatric cancer patients in 10–18 % of all infections and up to 33 % of cases of bacteraemia [16]. In our study, the majority of the patients with S. aureus infection had central venous catheter (CVC) (66 %) and primary bacteraemia. Mortality from S. aureus in paediatric oncologic setting is reported at 2.3 % [16]. No patient with S. aureus BSI died in our study.

Viridans group Streptococcus was the third in rank order of BSI in our patients. Infections due to viridans group Streptococcus have been seen especially in patients with AML, corresponding to ~25 % of all BSIs in these patients [17]. The mortality rate is high as 20 % [18]. In institutions with a high prevalence of this agent, the initial empirical antibiotic therapy includes vancomycin [19].

Among Gram-negative isolates, Enterobacteriaceae were predominant, with E. coli followed by K. pneumoniae as the main agents.

Pseudomonas aeruginosa was the main agent among non-fermenting bacteria and despite improvement in recent years, the prognosis of infection due this agent in this patient population remains poor, with case fatality rates exceeding 20 % [20]. Our institution has been treating patients with FN according to risk stratification for life-threatening infections; patients considered low risk receive moxifloxacin as outpatients, and high-risk patients receive cefepime as inpatients [7, 21].

We compared 69 positive BC episodes using phenotypic and molecular methods. The overall concordance was 78.2 % for final species identification, which is similar to a study conducted by Varani et al. in 2009 who found 79.2 % concordance between the two methods [22]. Comparing the two methods only for Gram-positive pathogens, the final species concordance identification was 89.6 %.

Recent studies have observed an increase in methicillin-resistant Staphylococcus infections, especially in patients with haematological malignancies; 70–80 % among CoNS and 25–30 % among S. aureus [23]. We detected 78 % methicillin resistance in BSI caused by S. aureus. The molecular method was able to detect the mecA gene in 93 % of these cases. Two samples were discordant, and when the molecular method was applied directly to the isolated colonies, it was concordant with the phenotypic method. Samples in which the phenotypic method shows methicillin resistance and the mecA gene is not found must be evaluated for mecC, and if this is present, patients must be managed as if they have methicillin-resistant S. aureus [24].

Resistance to vancomycin among enterococci has emerged as a general problem and is now found in patients with FN [25]. We found that 5 % of BSIs were due to Enterococcus spp., and 50 % were VRE. In our study we had one patient with VRE BSI infection who died 4 days after he had a positive BC and 1 day after the final result of BC emerged, which reflects the importance of early diagnosis. The molecular method was concordant in 100 % of the cases. Early identification of VRE is important beyond the therapeutic approach because this contributes to infection control procedures to avoid the spread of these microorganisms.

Three of our four P. aeruginosa isolates were resistant to carbapenems by the phenotypic method, which agreed with our molecular method in 50 % of cases. In the two discordant samples, we tested for the presence of the MBL genes directly from the isolated colonies; one of which was positive for blaSPM and one negative for MBL genes. This suggests that another mechanism was responsible for carbapenem resistance, such as porin loss or efflux systems.

Even though the rate of infection with carbapenem-resistant Acinetobacter spp. is increasing, we found only one infection due to A. baumannii and it was susceptible to cefepime and carbapenems.

Enterobacteriaceae were predominant among Gram-negative isolates, and the main agent was E. coli, followed by K. pneumoniae, with a high concordance in final species identification between the two methods.

The literature shows an incidence of ESBL among E. coli varying from 12.6 to 48.3 % [26, 27]. In our study, 60 % of E. coli were ESBL producers, showing 78.5 % concordance with the molecular method. Three samples were discordant. Two of those had a phenotypic profile of ESBL and no resistance genes were detected. The other sample was susceptible to cephalosporins, and we found blaCTX-M, which was not confirmed in an additional test performed directly on the isolated colony. The patient received treatment with cefepime and had a good outcome.

Regarding fungal infection, our molecular method was able to identify yeasts, with the exception of one episode of C. lusitaniae that was responsible for one death. This is an uncommon species of Candida in these patients and it is important to note that it can be resistant to amphotericin B [28].

The impact of early appropriate antibiotic therapy on patient survival has been demonstrated in previous studies [1, 12, 29, 30]. In our study, we showed that only one of six patients who died within 14 days after BSI had adequate initial empirical therapy. Therapy was modified in five cases based on Gram staining of the positive BC (Period 1) and after the final results, three treatments remained inadequate. The molecular method was able to identify the microorganism and resistance gene in two of these three cases.

Early identification of the causative organism and resistance genes such as vanA for enterococci and MBL for P. aeruginosa is crucial for adequate antimicrobial therapy, especially in paediatric neutropenic patients. Our empirical treatment approach does not take into account the resistant microorganisms shown in our study.

A limitation of the method is that PCR is so sensitive that we could not exclude the risk of false positive from skin contamination during blood culture collection particularly for CoSN. Other molecular mechanisms of resistance could be added since our “in house” multiplex is done in an open qPCR plataform.

Conclusions

The addition of molecular tests, including qPCR, for identification of pathogens and detection of antimicrobial resistance genes to the classical phenotypic tests in BSI is particularly relevant in paediatric cancer patients.

Abbreviations

AML: 

Acute myeloid leukaemia

BC: 

Blood culture

BSI: 

Bloodstream infection

CoNS: 

Coagulase-negative Staphylococcus

CVC: 

Central venous catheter

ESBL: 

Extended spectrum β-lactamase

FN: 

Febrile neutropenia

ICU: 

Intensive care unit

MIC: 

Minimum inhibitory concentration

qPCR: 

quantitative polymerase chain reaction

VRE: 

Vancomycin-resistant enterococcus

Declarations

Acknowledgements

This study was supported by a grant from Fundação de Amparo a Pesquisa do estado de São Paulo (FAPESP) Brazil.

Funding

There has been no significant financial support for this work that could have influenced its outcome.

Availability of data and materials

All data contained within this article.

Authors’ contributions

FC carried out the data clinical acquisition, data analysis and draft the manuscript; PC; LCM and ASP participated of the design of the study, MGQ performed the PCR experiments and provided the molecular analyses; ACCP participated in the design and coordination of study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by the Clinical Research Ethics Committee of the Hospital. All subjects signed the inform term consent.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Paediatric Oncology, Universidade Federal de São Paulo, Rua Botucatu 743, São Paulo, 04037020, Brazil
(2)
Infectious Diseases Division, Universidade Federal de São Paulo, São Paulo, Brazil

References

  1. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–38.View ArticlePubMedGoogle Scholar
  2. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958–66.View ArticlePubMedGoogle Scholar
  3. Santolaya ME, Farfan MJ, De LM V, Cocina M, Santelices F, Alvarez AM, et al. Diagnosis of bacteremia in febrile neutropenic episodes in children with cancer: microbiologic and molecular approach. Pediatr Infect Dis J. 2011;30:957–61.View ArticlePubMedGoogle Scholar
  4. Menezes LC, Rocchetti TT, Bauab KC, Cappellano P, Quiles MG, Carlesse F, et al. Diagnosis by real-time polymerase chain reaction of pathogens and antimicrobial resistance genes in bone marrow transplant patients with bloodstream infections. BMC Infect Dis. 2013;13:166.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31.View ArticlePubMedGoogle Scholar
  6. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2–8.View ArticlePubMedGoogle Scholar
  7. Petrilli A, Altruda CF, Alberto Pires PC. Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. Pediatr Blood Cancer. 2007;49:682–6.View ArticlePubMedGoogle Scholar
  8. Quiles MG, Menezes LC, Bauab KC, Gumpl EK, Rocchetti TT, Palomo FS, et al. Diagnosis of bacteremia in pediatric oncologic patients by in-house real-time PCR. BMC Infect Dis. 2015;15:283.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–304.View ArticlePubMedGoogle Scholar
  10. Pizzo PA. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient. J Pediatr. 1981;98:341–54.View ArticlePubMedGoogle Scholar
  11. Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2010;29:53–9.View ArticlePubMedGoogle Scholar
  12. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–40.View ArticlePubMedGoogle Scholar
  13. Pereira CA, Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR, et al. Nosocomial bloodstream infections in Brazilian pediatric patients: microbiology, epidemiology, and clinical features. PLoS One. 2013;8:e68144.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Cortez D, Rodriguez N, Benadof D, Zamorano A, Tordecilla J. Bacteremia in cancer patients. Experience in a pediatric hospital. Rev Chil Infectol. 2012;29:164–8.View ArticleGoogle Scholar
  15. Aslan S, Citak EC, Yis R, Degirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol. 2012;52:203–8.View ArticlePubMedGoogle Scholar
  16. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus infections in pediatric oncology patients: high rates of antimicrobial resistance, antiseptic tolerance and complications. Pediatr Infect Dis J. 2013;32:124–8.View ArticlePubMedGoogle Scholar
  17. Han SB, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, et al. Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children. BMC Infect Dis. 2013;13:273.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 2004;22:1222–7.View ArticlePubMedGoogle Scholar
  19. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009;31:623–9.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Vuotto F, Berthon C, Lemaitre N, Duhamel A, Balkaran S, Le RE, et al. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Am J Infect Control. 2013;41:527–30.View ArticlePubMedGoogle Scholar
  21. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34:87–91.View ArticlePubMedGoogle Scholar
  22. Varani S, Stanzani M, Paolucci M, Melchionda F, Castellani G, Nardi L, et al. Diagnosis of bloodstream infections in immunocompromised patients by real-time PCR. J Infect. 2009;58:346–51.View ArticlePubMedGoogle Scholar
  23. Solis Y, Alvarez AM, Fuentes D, de la Barra D, Aviles CL, Becker A, et al. Bloodstream infections in children with cancer and high risk fever and neutropenia episodes in six hospitals of Santiago, Chile between 2004 and 2009. Rev Chil Infectol. 2012;29:156–62.View ArticleGoogle Scholar
  24. Shore AC, Deasy EC, Slickers P, Brennan G, O’Connell B, Monecke S, et al. Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:3765–73.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Allendorf SD, Cortez A, Heinemann MB, Harary CM, Antunes JM, Peres MG, et al. Rabies virus distribution in tissues and molecular characterization of strains from naturally infected non-hematophagous bats. Virus Res. 2012;165:119–25.View ArticlePubMedGoogle Scholar
  26. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299–307.View ArticlePubMedGoogle Scholar
  27. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sanchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66:657–63.View ArticlePubMedGoogle Scholar
  28. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9:e101510.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Petrilli AS, Bianchi A, Kusano E, Melaragno R, Naspitz C, Mendonca JS, et al. Fever and granulocytopenia in children with cancer: a study of 299 episodes with two treatment protocols in Brazil. Med Pediatr Oncol. 1993;21:356–61.View ArticlePubMedGoogle Scholar
  30. Pizzo PA, Commers J, Cotton D, Gress J, Hathorn J, Hiemenz J, et al. Approaching the controversies in antibacterial management of cancer patients. Am J Med. 1984;76:436–49.View ArticlePubMedGoogle Scholar

Copyright

Advertisement